Incyte Presents P-II Trial (SCRATCH-AD) Results of Opzelura (ruxolitinib) for the Treatment of Atopic Dermatitis at RAD 2023
Shots:
- The P-II trial evaluating Opzelura (1.5%) in 49 adult patients aged 18-65yrs. with AD. The trial met its 1EPs i.e., improvement in itch was sustained with a mean (SE) change from baseline in mPP-NRS of –3.1 @ 12hrs. post-Opzelura application
- Improvement in itch was also observed with continued treatment as evidenced by the mean (SE) change from baseline in PP-NRS increasing through 29 Days, improvement in AD symptoms with Opzelura treatment increased over time, and was well tolerated with no serious TEAEs during the 28-day & no patients discontinued treatment due to a TEAE
- Opzelura (selective JAK1/JAK2 inhibitor) was approved in the US for the topical short-term & non-continuous chronic treatment of mild to mod. AD in non-immunocompromised patients
Ref: Businesswire | Image: Incyte
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
